摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6aS,12bR)-(+/-)-6a,7-dihydro-2,4-dimethyl-6H,12bH-<1>benzopyrano<3',4':5,4>pyrano<2,3-d>pyrimidine-1,3(2H,4H)-dione | 83477-01-4

中文名称
——
中文别名
——
英文名称
(6aS,12bR)-(+/-)-6a,7-dihydro-2,4-dimethyl-6H,12bH-<1>benzopyrano<3',4':5,4>pyrano<2,3-d>pyrimidine-1,3(2H,4H)-dione
英文别名
(1R,10S)-4,6-dimethyl-8,12-dioxa-4,6-diazatetracyclo[8.8.0.02,7.013,18]octadeca-2(7),13,15,17-tetraene-3,5-dione
(6aS,12bR)-(+/-)-6a,7-dihydro-2,4-dimethyl-6H,12bH-<1>benzopyrano<3',4':5,4>pyrano<2,3-d>pyrimidine-1,3(2H,4H)-dione化学式
CAS
83477-01-4
化学式
C16H16N2O4
mdl
——
分子量
300.314
InChiKey
FZDZCSYWZKEFFE-JOYOIKCWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    59.1
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Catalytic Intramolecular Cycloaddition Reactions by Using a Discrete Molecular Architecture
    作者:Bijan Roy、Anthonisamy Devaraj、Rupak Saha、Suprita Jharimune、Ki-Whan Chi、Partha Sarathi Mukherjee
    DOI:10.1002/chem.201702507
    日期:2017.11.7
    utilised as a molecular vessel to perform intramolecular cycloaddition reactions of O‐allylated benzylidinebarbituric acid derivatives inside its confined nanospace. The presence of a catalytic amount of MT‐1 promoted [4+2] cycloaddition reactions in a regio‐ and stereoselective manner, yielding the corresponding penta/tetracyclouracil derivatives in good yields under mild reaction conditions. This protocol
    离散四方筒状的络合物(MT-1 )已被合成的协调驱动的自组装基于咔唑的tetraimidazole供体的大号和(II)90°受体,即,[顺式- (DPPF)的Pd (OTF)2 ](DPPF二苯基膦二=,光学传递函数= CF 3 SO 3 - )。复合MT-1通过多核NMR,ESI-MS和单晶X射线衍射分析(SCXRD)对其进行了表征,表明其对称的四面管状结构,具有由四个芳香壁描述的大空腔。该配位笼成功地用作分子容器,在其受限的纳米空间内进行了O-烯丙基化苄基巴比妥酸生物的分子内环加成反应。催化量MT-1的存在以区域和立体选择性的方式促进了[4 + 2]环加成反应,在温和的反应条件下,以高收率得到了相应的五/四环尿嘧啶生物。与在高温回流条件或固态熔体反应(SSMRs)下合成相似的苯并嘧啶二酮衍生物的文献报道相比,该方案很有趣。
  • Buback, Michael; Gerke, Kerstin; Ott, Christian, Chemische Berichte, 1994, vol. 127, # 11, p. 2241 - 2248
    作者:Buback, Michael、Gerke, Kerstin、Ott, Christian、Tietze, Lutz F.
    DOI:——
    日期:——
  • Highly stereo and chemoselective synthesis of tetra and pentacyclic frameworks using Solid-State Melt Reaction (SSMR)
    作者:Manickam Bakthadoss、Govindan Sivakumar
    DOI:10.1016/j.tetlet.2014.01.126
    日期:2014.3
    Benzopyran fused tetra and pentacyclic frameworks have been synthesized by the domino Knoevenagel hetero Diels-Alder (DKHDA) reaction using various 1,3-diones with O-allylated salicylaldehydes and O-propargylated salicylaldehydes in a solvent and catalyst free condition via Solid-State Melt Reaction (SSMR). The reaction requires only a single step operation thus providing potentially bioactive polycyclic heterocycles in high yields. (C) 2014 Elsevier Ltd. All rights reserved.
  • Tietze, Lutz-F.; Stegelmeier, Hartmut; Harms, Klaus, Angewandte Chemie, 1982, vol. 94, # 11, p. 868 - 869
    作者:Tietze, Lutz-F.、Stegelmeier, Hartmut、Harms, Klaus、Brumby, Thomas
    DOI:——
    日期:——
  • TIETZE, V. L. -F.;STEGELMEIER, H.;HARMS, K.;BRUMBY, T., ANGEW. CHEM., 1982, 94, N 11, 868-869
    作者:TIETZE, V. L. -F.、STEGELMEIER, H.、HARMS, K.、BRUMBY, T.
    DOI:——
    日期:——
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione